Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial

For patients with unresectable hepatocellular carcinoma (HCC) who cannot benefit from resection, transplantation, or ablation, the oral multikinase inhibitor sorafenib at the approved dose of 800 mg/day is the standard first-line systemictreatment.[1 –3] Recently, lenvatinib was shown to be non-inferior to sorafenib for overall survival (OS) for first-line systemic treatment of HCC.[4] Since the approval of sorafenib in 2008, one of the most important unmet needs in the treatment of HCC has been the development of agents that improve outcomes after disease progression during sorafenib treatment.

Source: Journal of Hepatology - April 25, 2018 Category: Gastroenterology Authors: Richard S. Finn, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, Gy örgy Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, René Gerolami, Chiara Caparello, Roniel Cabrera, Charissa Chang, Weijing Sun, Marie-Aude LeBerre, Annette Baumhauer, Ge Source Type: research